Document EMERGENT BIOSO LUTIONS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase

EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year

First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year

First Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior year

First Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior year

First Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior year

Reaffirmed FY 2025 Guidance

GAITHERSBURG, Md., May 7, 2025-Emergent BioSolutions Inc. (NYSE EBS) today reported financial results for the first quarter ended March 31, 2025.

Over the past 12 months, we have been executing our multi-year strategic plan to stabilize the company, streamlining operations with an eye toward driving profitability and transforming the company to achieve long-term, sustainable growth built on Emergent's strengths and unique capabilities, said Joe Papa, president and CEO of Emergent. We believe our solid first-quarter results are marked by revenues within our guidance range, overall increased profitability margins, increased cash on hand and improved cash flow, further demonstrating that our disciplined approach is setting the momentum for our continued turnaround actions this year. We remain confident in our 2025 financial guidance and anticipate delivering a strong second half of the year.

FINANCIAL HIGHLIGHTS(1)

RECENT BUSINESS UPDATES

Announced the exercise of contract option and modification valued at approximately $20.0 million to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

Received contract option valued at approximately $16.7 million to continue development collaboration with BARDA on Ebanga (ansuvimab-zykl) treatment for Ebola

Gained exclusive commercial rights to KLOXXADO (naloxone HCI) Nasal Spray in U.S. and Canada from Hikma Pharmaceuticals Hikma received Health Canada approval for the product

Announced investment agreement and pursuit of a strategic relationship for next-generation product candidates with Rocketvax Ltd

Secured approximately $27.0 million in international orders targeted for delivery in 2025 associated with medical countermeasures ( MCM ) portfolio

Completed the sale of our Baltimore-Bayview facility for $36.5 million

Earned $50.0 million in development milestone payments from Bavarian Nordic as part of the sale of the Travel Health Business, $30.0 million of which was paid during the quarter

Announced that Board of Directors authorized the repurchase of up to $50.0 million of the Company's common stock on or before March 27, 2026

Secured a three-year agreement valued at approximately $65.0 million to supply the Ontario Ministry of Health with NARCAN Nasal Spray

FIRST QUARTER 2025 FINANCIAL PERFORMANCE (1)

The Company uses the following categories in discussing revenues

NARCAN - comprises contributions from NARCAN Nasal Spray

Anthrax MCM - comprises contributions from CYFENDUS , previously known as AV7909, BioThrax , Anthrasil and Raxibacumab

Smallpox MCM - comprises contributions from ACAM2000 , VIGIV CNJ-016 and TEMBEXA

Other Products - comprises contributions from BAT and RSDL (3)

All Other Revenues - comprises revenues from the Services operating segment and contracts and grants revenues

Product Sales, net (4)

For Q1 2025, revenues from NARCAN (naloxone HCl) Nasal Spray decreased $73.2 million, or 62%, as compared with Q1 2024. The decrease was primarily driven by lower sales of OTC NARCAN and lower Canadian retail sales of branded NARCAN , primarily driven by an unfavorable price and volume mix.

For Q1 2025, revenues from Anthrax MCM products decreased $8.0 million, or 14%, as compared with Q1 2024. The decrease reflects the impact of the timing of sales related to CYFENDUS , partially offset by the timing of sales related to Anthrasil . Anthrax vaccine product sales are primarily made under annual purchase options exercised by the U.S. government (the "USG"). Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.

For Q1 2025, revenues from Smallpox MCM products increased $56.2 million, or 112%, as compared with Q1 2024. The increase was primarily due to higher ACAM2000 and TEMBEXA sales due to timing, partially offset by lower VIGIV CNJ-016 , due to timing. Fluctuations in revenues from Smallpox MCM result from the timing of the exercise of annual purchase options in the existing procurement contracts, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.

For Q1 2025, revenues from Other Product sales decreased $47.0 million, or 95%, as compared with Q1 2024. The decrease was primarily due to lower BAT sales due to timing and no RSDL product sales due to the sale of RSDL to SERB Pharmaceuticals in 2024.

For Q1 2025, revenues from Services decreased $11.3 million, or 61%, as compared with Q1 2024. The decrease was primarily attributable to revenue from the Company's Camden facility in the prior period, which was sold to Bora Pharmaceuticals in the third quarter of 2024, partially offset by an increase in production at the Company's Winnipeg facility.

Contracts and Grants

For Q1 2025, revenues from contracts and grants increased $5.1 million, or 64%, as compared with Q1 2024. The increase was primarily due to development work in connection with Ebanga .

Cost of Product and Services Sales, Net

For Q1 2025, cost of product and services sales, net decreased $56.1 million, or 39%, as compared with Q1 2024. The decrease was driven by decreases in cost of Commercial Product sales of $27.6 million, cost of Services of $16.5 million and cost of MCM Product sales of $12.0 million.

Research and Development Expenses

For Q1 2025, R D expenses were consistent at $15.1 million as compared with Q1 2024.

Selling, General and Administrative Expenses

For Q1 2025, SG A expenses decreased $32.3 million, or 38%, as compared with Q1 2024. The decrease was primarily due to decreases in compensation and other employee costs as a result of the restructuring initiatives that began during the first quarter of 2023, a reduction in marketing costs, lower professional services fees related to general corporate initiatives in 2024, including organizational transformation consulting fees and lower legal service fees.

ADDITIONAL FINANCIAL INFORMATION(1)

Capital Expenditures

For Q1 2025, capital expenditures decreased largely due to lower development activities across the Company's facilities.

REPORTABLE SEGMENT INFORMATION

The Company manages the business with a focus on three operating segments (1) a Commercial Products segment consisting of NARCAN (2) a MCM Products segment consisting of Anthrax - MCM, Smallpox - MCM and Other products and (3) a services segment consisting of our Bioservices offerings ("Services"). Commercial Products and MCM Products are our two reportable segments. In the first quarter of 2025, the Company's determined that its Services operating segment no longer meets the quantitative thresholds of a reportable segment and did not meet the aggregation criteria set forth in Accounting Standards Codification 280, Segment Reporting, and as such is categorized within "All other revenues" along with "Contracts and Grants". The Company evaluates the performance of these reportable segments based on revenues and segment adjusted gross margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but does not include inter-segment services. The Company does not allocate contracts and grants revenue, R D, SG A, amortization of intangible assets, interest and other income (expense) or taxes to its evaluation of the performance of these segments.

FIRST QUARTER 2025 REPORTABLE SEGMENT RESULTS

Cost of Commercial Product sales decreased $27.6 million, or 53%, to $24.5 million for the three months ended March 31, 2025. The decrease was primarily due to lower sales of OTC NARCAN and lower Canadian retail sales of branded NARCAN .

Commercial Products gross margin decreased $45.7 million, or 80%, to $11.3 million for the three months ended March 31, 2025. Commercial Products gross margin percentage decreased 23 percentage points to 25% for the quarter ended March 31, 2025. The decrease was largely due to lower sales of OTC NARCAN and lower branded NARCAN sales. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $9.5 million.

Cost of MCM product sales decreased $12.0 million, or 19%, to $50.2 million for the three months ended March 31, 2025. The decrease was primarily due to lower sales of BAT and CYFENDUS , due to timing, coupled with no RSDL product sales due to the sale of RSDL to SERB, partially offset by an increase in Anthrasil and ACAM2000 sales, due to timing.

MCM Products gross margin increased $13.2 million, or 15%, to $99.6 million for the three months ended March 31, 2025. MCM Products gross margin percentage increased 8 percentage points to 64% for the quarter ended March 31, 2025. The increase was primarily due to a favorable sales mix which was weighted more heavily towards higher margin products and a decrease in shutdown costs compared to the prior quarter. MCM Product segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $6.8 million, inventory step-up provision of $1.8 million and restructuring costs of $(0.8) million.

2025 FINANCIAL FORECAST

The Company provides the following updated financial forecast for full year 2025 and Q2 2025, reflecting management's expectations based on the most current information available.

(1) All financial information included in this release is unaudited.

(2) See "Non-GAAP Financial Measures" and the Reconciliation of Non-GAAP Financial Measures tables for the definitions and reconciliations of these non-GAAP financial measures to the most closely related GAAP financial measures.

(3) Our MCM Products revenue in 2025 and forecasted revenue excludes revenues related to RSDL , which was sold during the third quarter of 2024.

(4)Product sales, net are reported net of variable consideration including returns, rebates, wholesaler fees and prompt pay discounts in accordance with GAAP.

(5) Our Commercial Products forecast consists of revenues for NARCAN Nasal Spray and revenues from distribution of Kloxxado naloxone HCl nasal spray 8 mg pursuant to an agreement with Hikma Pharmaceuticals PLC in January 2025.

CONFERENCE CALL, PRESENTATION SUPPLEMENT AND WEBCAST INFORMATION

Company management will host a conference call at 5 00 pm eastern time today, May 7, 2025, to discuss these financial results. The conference call and presentation supplement can be accessed from the Company's website or through the following

Advanced registration is required.

Visit https register.vevent.com register BI55c44c8318724673999b4e3fa8f61b7b to register and receive an email with the dial-in number, passcode and registrant ID.

Visit https edge.media-server.com mmc p xrqjtg3j

A replay of the call can be accessed from the Emergent website.

ABOUT EMERGENT BIOSOLUTIONS INC.

NON-GAAP FINANCIAL MEASURES

In the accompanying analysis of financial information, we sometimes use information derived from consolidated and segment financial information that may not be presented in our financial statements or prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Certain of these financial measures are considered not in conformity with GAAP ("non-GAAP financial measures") under the United States Securities and Exchange Commission ("SEC") rules. Specifically, we have referred to the following non-GAAP financial measures

Adjusted Net Income per Diluted Share

Adjusted EBITDA Margin

Adjusted Gross Margin

Adjusted Gross Margin %

Segment Adjusted Gross Margin

Segment Adjusted Gross Margin %

We define Adjusted Net Income and Adjusted Net Income per Diluted Share, which are non-GAAP financial measures, as net income and net income per diluted share, respectively, excluding the impact of changes in fair value of financial instruments, acquisition and divestiture-related costs, severance and restructuring costs, loss on assets held for sale, inventory step-up provision, non-cash amortization charges, contingent consideration milestones, other income (expense) items and tax effect. We use Adjusted Net Income for the purpose of calculating Adjusted Net Income per Diluted Share. Management uses Adjusted Net Income per Diluted Share to assess total Company operating performance on a consistent basis. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provide management and investors with an additional understanding of our business operating results, including underlying trends.

We define Adjusted EBITDA, which is a non-GAAP financial measure, as net loss before income tax provision, interest expense, net, depreciation and amortization, excluding the impact of changes in fair value of financial instruments, acquisition and divestiture-related costs, severance and restructuring costs, loss on and assets held for sale, inventory step-up provision, contingent consideration milestones and other income (expense) items. We define Adjusted EBITDA Margin as Adjusted EBITDA divided by Total Revenues. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provides management and investors with a more complete understanding of our operating results, including underlying trends. In addition, EBITDA is a common alternative measure of operating performance used by many of our competitors. It is used by investors, financial analysts, rating agencies and others to value and compare the financial performance of companies in our industry, although it may be defined differently by different companies. Therefore, we also believe that this non-GAAP financial measure, considered along with corresponding GAAP financial measures, provides management and investors with additional information for comparison of our operating results with the operating results of other companies.

We define Adjusted Gross Margin, which is a non-GAAP financial measure, as Gross Margin, excluding the impact of intangible asset amortization, restructuring costs, changes in the fair value of financial instruments and inventory step-up provision. We define Adjusted Gross Margin %, which is a non-GAAP financial measure, as Adjusted Gross Margin as a percentage of Products and services sales, net.

We define Segment Adjusted Gross Margin, which is a non-GAAP financial measure, as a segment's Gross Margin excluding the respective impact of intangible asset amortization, restructuring costs, changes in the fair value of financial instruments and inventory step-up provision. We define Segment Adjusted Gross Margin %, which is a non-GAAP financial measure, as Segment Adjusted Gross Margin as a percentage of a segment's revenues.

Non-GAAP financial measures are not defined in the same manner by all companies and may not be comparable with other similarly titled measures of other companies. The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Non-GAAP financial measures should be considered in addition to, but not as a substitute for or superior to, the information contained in our Consolidated Statements of Operations and Consolidated Statements of Cash Flows. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this press release.

SAFE HARBOR STATEMENT

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements are based on our current intentions, beliefs, assumptions and expectations regarding future events based on information that is currently available. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any such forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasure ( MCM ) products, including CYFENDUS (Anthrax Vaccine Adsorbed (AVA) Adjuvanted), previously known as AV7909, ACAM2000 (Smallpox (Vaccinia) Vaccine, Live), VIGIV CNJ-016 (Vaccinia Immune Globulin Intravenous (Human)), BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), BioThrax (Anthrax Vaccine Adsorbed) EbangaTM (ansuvimab-zykl) and or TEMBEXA (brincidofovir) among others, as well as contracts related to development of medical countermeasures our ability to meet our commitments to quality and compliance in all of our manufacturing operations our ability to negotiate additional USG procurement or follow-on contracts for our MCM products that have expired or will be expiring the commercial availability and impact of a generic and competitive marketplace on future sales of NARCAN (naloxone HCL) Nasal Spray and over-the-counter NARCAN Nasal Spray our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations our ability to negotiate new or further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing related to our bioservices and under existing Bioservices contracts our ability to collect reimbursement for raw materials and payment of service fees from our Bioservices customers the results of pending government investigations and their potential impact on our business our ability to satisfy the conditions of the final settlement, and the potential impact of the final settlement agreement, including the funds to resolve the litigation, on our business our ability to comply with the operating and financial covenants required by (i) our term loan facility under a credit agreement, dated August 30, 2024, among the Company, the lenders from time to time party thereto and OHA Agency LLC, as administrative agent, (ii) our revolving credit facility under a credit agreement, dated September 30, 2024, among the Company, certain subsidiary borrowers, the lenders from time to time party thereto and Wells Fargo, National Association, as Agent, and (iii) our 3.875% Senior Unsecured Notes due 2028 our ability to maintain adequate internal control over financial reporting and to prepare accurate financial statements in a timely manner our ability to maintain sufficient cash flow from our operations to pay our substantial debt, both now and in the future our ability to

invest in our business operations as a result of our current indebtedness the impact of our share repurchase program the procurement of our product candidates by USG entities under regulatory authorities that permit government procurement of certain medical products prior to FDA marketing authorization, and corresponding procurement by government entities outside the United States our ability to realize the expected benefits of the sale of our travel health business to Bavarian Nordic, the sale of our Drug Product facility in Baltimore-Camden to Bora Pharmaceuticals Injectables Inc., a subsidiary of Bora Pharmaceuticals Co., Ltd., the sale of RSDL to BTG International Inc., a subsidiary of SERB Pharmaceuticals and the sale of our Baltimore-Bayview drug substance manufacturing facility to Syngene International the impact of the organizational changes we announced in January 2023, August 2023, May 2024 and August 2024 the success of our commercialization, marketing and manufacturing capabilities and strategy our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria our ability to realize the full benefits from our divestitures and sales of assets the impact of cybersecurity incidents, including the risks from the unauthorized access, interruption, failure or compromise of our information systems or those of our business partners, collaborators or other third parties and the accuracy of our estimates regarding future revenues, expenses, capital requirements and need for additional financing. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Readers should consider this cautionary statement, as well as the risks identified in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements.

Emergent , BioThrax , BaciThrax , BAT , Trobigard , Anthrasil , CNJ-016 , ACAM2000 , NARCAN , CYFENDUS , TEMBEXA and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners, including RSDL (Reactive Skin Decontamination Lotion), which was acquired by SERB on July 31, 2024.

Emergent BioSolutions Inc.

Consolidated Balance Sheets

(unaudited, in millions, except per share data)

Emergent BioSolutions Inc.

Consolidated Statements of Operations

(unaudited, in millions, except per share data)